CINECA IRIS Institutional Research Information System

ARTUSI, Carlo Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.307
EU - Europa 2.327
AS - Asia 1.347
SA - Sud America 70
OC - Oceania 61
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 9
Totale 8.173
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.222
IT - Italia 628
CN - Cina 595
IE - Irlanda 340
SE - Svezia 315
SG - Singapore 249
DE - Germania 165
FR - Francia 158
GB - Regno Unito 131
JP - Giappone 97
FI - Finlandia 91
ES - Italia 85
VN - Vietnam 76
NL - Olanda 70
CA - Canada 66
IN - India 66
KR - Corea 61
BE - Belgio 58
AU - Australia 54
PL - Polonia 54
AT - Austria 47
TR - Turchia 45
BR - Brasile 41
ID - Indonesia 38
UA - Ucraina 36
TW - Taiwan 33
CH - Svizzera 28
HK - Hong Kong 27
PT - Portogallo 20
SN - Senegal 19
RO - Romania 18
MX - Messico 16
GR - Grecia 14
IR - Iran 14
DK - Danimarca 12
RU - Federazione Russa 12
IL - Israele 11
BG - Bulgaria 10
CL - Cile 9
CZ - Repubblica Ceca 9
EG - Egitto 9
UZ - Uzbekistan 8
CO - Colombia 7
EU - Europa 7
NZ - Nuova Zelanda 7
CI - Costa d'Avorio 6
AR - Argentina 5
IS - Islanda 5
NO - Norvegia 5
PE - Perù 5
PH - Filippine 5
TH - Thailandia 5
TN - Tunisia 5
ZA - Sudafrica 5
SK - Slovacchia (Repubblica Slovacca) 4
EC - Ecuador 3
HU - Ungheria 3
MU - Mauritius 3
MY - Malesia 3
NG - Nigeria 3
AE - Emirati Arabi Uniti 2
BN - Brunei Darussalam 2
CY - Cipro 2
EE - Estonia 2
HN - Honduras 2
KZ - Kazakistan 2
SA - Arabia Saudita 2
SI - Slovenia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BY - Bielorussia 1
DZ - Algeria 1
GH - Ghana 1
HR - Croazia 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
NP - Nepal 1
PK - Pakistan 1
RS - Serbia 1
SV - El Salvador 1
Totale 8.173
Salva come PNG Salva come JPEG
Città #
Chandler 695
Dublin 338
Beijing 282
Fairfield 235
Ashburn 206
Singapore 192
Torino 181
Nyköping 168
Houston 148
Redwood City 135
Wilmington 133
Ann Arbor 131
Medford 108
Seattle 108
Princeton 103
Woodbridge 102
Cambridge 88
Fremont 86
Villeurbanne 81
Dearborn 70
Jacksonville 66
Turin 54
Dong Ket 53
Guangzhou 43
Vienna 43
Boston 42
Pisa 42
Hangzhou 40
New York 38
Milan 37
Warsaw 34
Jakarta 33
Helsinki 31
Santa Clara 27
Seoul 27
Madrid 26
Boardman 25
Brussels 24
Shanghai 22
Ottawa 21
Rome 20
Taipei 20
Chengdu 19
Istanbul 18
Norwalk 18
San Diego 17
Hebei 16
Hong Kong 16
Nanjing 15
Washington 15
London 13
Los Angeles 13
Tokyo 13
Jinan 12
Toronto 12
Changsha 10
Chicago 10
Hefei 10
Duncan 9
Oxford 9
Amsterdam 8
Düsseldorf 8
Falls Church 8
Genoa 8
Paris 8
Pune 8
Renton 8
Sydney 8
Barcelona 7
Bologna 7
Delhi 7
Edinburgh 7
Kunming 7
Melbourne 7
Minneapolis 7
Polska 7
Santiago 7
Wuhan 7
Zhengzhou 7
Abidjan 6
Berlin 6
Cincinnati 6
Gazi 6
Groslay 6
Nashville 6
Pamplona 6
Riverton 6
Rochester 6
Tejupilco de Hidalgo 6
Trento 6
Valencia 6
Zurich 6
Antwerp 5
Bethesda 5
Curitiba 5
Gainesville 5
Hanover 5
Köln 5
Mountain View 5
New Delhi 5
Totale 4.862
Salva come PNG Salva come JPEG
Nome #
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. 718
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience 430
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study. 331
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. 326
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 315
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome? 262
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. 257
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients 256
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? 250
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 182
Natalizumab in Multiple Sclerosis: Long-Term Management 131
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 127
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail 124
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic 119
Neurological comorbidity and severity of COVID-19 106
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review 104
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 88
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study 82
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 82
Beyond Nine Years of Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease 80
3 years comparison between duodopa and Deep Brain Stimulation 80
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications 77
Pisa syndrome in Parkinson's disease is associated with specific cognitive alterations 73
The dominant subthalamic nucleus: A gait analysis study 72
Earlier versus later subthalamic deep brain stimulation in Parkinson's disease 71
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 71
Orthostatic hypotension in Parkinson disease: Impact on health care utilization 68
Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming 68
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 67
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study 67
Continuous intraduodenal L-dopa/carbidopa gel infusion improves nocturnal sleep in advanced Parkinson’s disease 66
Complex therapies for advanced Parkinson’s disease: what is the role of doctor-patient communication? 66
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 66
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 65
Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech 65
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 64
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 63
The still under-investigated role of cognitive deficits in PML diagnosis 63
Ultrasound-guided botulinum toxin-A for sialorrhea: a 2-year prospective study 62
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease 62
Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson’s Disease? 62
Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic 62
Clinical efficacy of different stimulation frequencies on dyskinesias and dystonias in subthalamic nucleus deep brain stimulation patients with parkinson's disease 60
Effects of 80 Hz stimulation on gait in STN-DBS treated PD patients 60
Parkinsonism–hyperpyrexia syndrome and deep brain stimulation 60
Changing the Side of Pisa Syndrome: A Case of Over-Recovery with Botulinum Toxin 59
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors 58
COVID-19 and Parkinson's Disease: What We Know So Far? 57
Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia 56
Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution 56
Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1 55
Time to onset and duration of botulinum toxin efficacy in movement disorders 55
Differential response to pallidal deep brain stimulation among monogenic dystonias: Systematic review and meta-analysis 54
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease 54
Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease 54
Peripheral neuropathy in Parkinson’s disease patients treated with duodenal levodopa/carbidopa infusion: A clinical and electrophysiological follow-up study 52
Home monitoring of motor fluctuations in Parkinson’s disease patients 52
A new index to assess turning quality and postural stability in patients with Parkinson's disease 52
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis 50
Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum 50
Tuning Deep Brain Stimulation related depression by frequency modulation: a case report 49
Friedreich's ataxia patients and caregivers information seeking behaviour 48
Low frequency subthalamic stimulation and event-related potentials in Parkinson disease 48
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease 48
COVID-19 in Parkinson's disease: Report on prevalence and outcome 47
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential 47
Onset of Covid-19 with impaired consciousness and ataxia: a case report 45
Digital work engagement among Italian neurologists 45
Prevalence and burden of dysautonomia in advanced Parkinson's disease 44
Parkinson's clinical features after 30 years of disease: A study from patients treated by subthalamic nucleus stimulation 43
Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD 43
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials 43
G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome 43
Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson’s disease 42
Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment 42
Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report 42
Telemedicine in Neurological Disorders: Opportunities and Challenges 41
Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis 41
Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic 41
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach 40
Neurological comorbidities and COVID-19-related case fatality: A cohort study 40
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study 37
Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection 36
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 35
Subthalamic deep brain stimulation and trunk posture in Parkinson's disease 35
Prospective assessment of peripheral neuropathy in duodopa treated patients 34
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience 34
Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety 34
Levodopa-Induced Neuropathy: A Systematic Review 33
Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study 31
Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases 29
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects 28
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach 27
Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson’s disease patients 23
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 22
Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease 22
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review 20
Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort 19
15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson’s disease patient with Parkin gene mutation: a case report 19
Gait and axial postural abnormalities correlations in Parkinson's disease: A multicenter quantitative study 17
Totale 8.301
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.678
article - articoli 0
book - libri 0
conference - conferenze 3.610
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.288
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020793 0 0 0 121 84 101 100 87 79 79 73 69
2020/20211.090 63 79 59 137 82 108 46 79 98 87 85 167
2021/20221.279 81 44 52 98 75 62 64 61 53 94 317 278
2022/20231.927 203 196 52 222 166 463 111 114 165 71 105 59
2023/2024957 114 157 44 49 53 137 35 84 4 83 59 138
2024/2025353 53 176 77 47 0 0 0 0 0 0 0 0
Totale 8.481